- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. ] Zilovertamab
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P99201 |
| Brand: | MCE |
| CAS: | - |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Zilovertamab] |
Summary
In Vitro
Zilovertamab (25 and 50 µg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation
[1]
.
Zilovertamab (50 µg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | CaOV3, CaOV3CisR, PEO1, and PEO4 cells |
| Concentration: | 25 and 50 µg/mL |
| Incubation Time: | 72 hours |
| Result: | Reduced the proliferation of CaOV3, CaOV3CisR and PEO1. |
Western Blot Analysis [1]
| Cell Line: | CaOV3, CaOV3CisR, PEO1, and PEO4 cells |
| Concentration: | 50 µg/mL |
| Incubation Time: | 72 hours |
| Result: | Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05458297 | Merck Sharp & Dohme LLC |
Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Follicular Lymphoma|Richter Transformation Lymphoma
|
July 21, 2022 | Phase 2 |
| NCT04501939 | University of California, San Diego|Oncternal Therapeutics, Inc |
Chronic Lymphocytic Leukemia
|
August 6, 2020 | Phase 2 |
| NCT02860676 | University of California, San Diego |
Chronic Lymphocytic Leukemia
|
November 3, 2016 | Phase 1 |
| NCT05139017 | Merck Sharp & Dohme LLC |
DLBCL|Diffuse Large B-Cell Lymphoma
|
January 14, 2022 | Phase 2|Phase 3 |
| NCT02776917 | Barbara Parker, MD|Oncternal Therapeutics, Inc|University of California, San Diego |
Breast Neoplasms
|
August 15, 2018 | Phase 1 |
| NCT02222688 | Thomas Kipps|University of California, San Diego |
Chronic Lymphocytic Leukemia
|
August 8, 2014 | Phase 1 |
| NCT03088878 | Oncternal Therapeutics, Inc|California Institute for Regenerative Medicine (CIRM)|University of California, San Diego|Pharmacyclics LLC. |
B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma
|
January 3, 2018 | Phase 1|Phase 2 |
| NCT05562830 | Merck Sharp & Dohme LLC |
Urothelial Carcinoma
|
November 15, 2022 | Phase 1|Phase 2 |
| NCT05431179 | Oncternal Therapeutics, Inc|Pharmacyclics LLC. |
Lymphoma, Mantle-Cell|Lymphoma|Lymphoproliferative Disorders|Lymphatic Diseases|Immunoproliferative Disorders|Immune System Diseases|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell
|
September 2022 | Phase 3 |
| NCT03833180 | VelosBio Inc. |
Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|Richter Transformation Lymphoma|Burkitt Lymphoma|Lymphoplasmacytoid Lymphoma|T-cell Non-Hodgkin Lymphoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia
|
March 14, 2019 | Phase 1 |
| NCT05156905 | University of California, San Diego |
Metastatic Castration-resistant Prostate Cancer
|
June 16, 2022 | Phase 1 |
| NCT05406401 | Merck Sharp & Dohme LLC |
Lymphoma, Large B-Cell, Diffuse (DLBCL)
|
July 14, 2022 | Phase 2 |
| NCT04504916 | VelosBio Inc. |
Triple-negative Breast Cancer|Non-squamous Non-small-cell Lung Cancer|NSCLC|Estrogen-receptor-positive Breast Cancer|Progesterone-receptor-positive Breast Cancer|Estrogen-receptor-negative Breast Cancer|ER-negative Breast Cancer|Progesterone-receptor Negative Breast Cancer|PR-negative Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer|PR-positive Breast Cancer|Platinum-resistant Ovarian Cancer|Gastric Cancer|Pancreatic Cancer
|
October 7, 2020 | Phase 2 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.